A Pill That Matches Injectable Power
Cardiovascular disease kills more people globally than any other condition, and elevated LDL cholesterol is among its most modifiable risk factors. The most powerful drugs for lowering LDL — injectable PCSK9 inhibitors like evolocumab and alirocumab — can reduce LDL by 50-60% on top of statin therapy. They work extremely well. But they require injection, typically monthly or biweekly, which creates adherence problems and limits adoption in populations who could benefit.
A new drug called enlicitide appears to match that level of LDL reduction in pill form. Results from a large clinical trial show approximately 60% LDL reduction for patients taking enlicitide daily — performance that was previously thought to require injectable therapy.
Why This Is Significant
The cardiovascular medication landscape has a well-documented adherence problem. Statins, which are oral and relatively cheap, are taken inconsistently by many patients who would benefit from them. PCSK9 inhibitors, despite their efficacy, have faced adoption barriers including injection aversion, cost, and the need for healthcare provider involvement in some settings.
A once-daily pill with PCSK9 inhibitor-level efficacy addresses both of these problems simultaneously. The oral formulation removes the injection barrier, and if enlicitide can achieve competitive pricing, it could bring powerful cholesterol management to the much larger population inadequately treated by statins alone.
The Trial Details
The major trial enrolled thousands of patients with elevated cardiovascular risk across multiple sites. Participants were typically already on statin therapy, meaning the 60% LDL reduction represents additional benefit on top of standard care. Safety data from the trial appeared consistent with the drug's mechanism of action, with no unexpected serious adverse events at the headline level.
The Mechanism
Enlicitide works by blocking PCSK9, an enzyme that degrades LDL receptors in the liver. By inhibiting PCSK9, the drug allows liver cells to maintain more LDL receptors, which then clear more LDL from the bloodstream. The existing injectable PCSK9 inhibitors work on the same mechanism using biologic antibodies; enlicitide achieves PCSK9 inhibition through a different molecular approach that is orally bioavailable.
Achieving oral bioavailability for PCSK9 inhibition has been a significant scientific challenge. Peptide-based drugs are typically broken down in the digestive system before reaching the bloodstream — which is why existing PCSK9 inhibitors require injection. The technical achievement behind enlicitide is solving this delivery problem.
The Competitive Landscape
Enlicitide is not the only oral PCSK9 inhibitor in development. Merck and several other companies have programs in various stages targeting the same space. The scale and outcomes of the enlicitide trial put it in a strong position for regulatory submission, and given the established clinical need, priority review designations are possible.
Implications for Cardiovascular Care
If enlicitide reaches market at competitive pricing, it could reshape the treatment algorithm for high-risk cardiovascular patients. Currently, patients who don't reach LDL targets on statins face a significant escalation step — injectable therapy with all its associated barriers. An oral option at equivalent efficacy changes that calculus entirely.
For the millions of patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, or other conditions requiring aggressive LDL management, an effective daily pill represents a genuinely better treatment experience — and better adherence translates directly into fewer heart attacks and strokes over time.
This article is based on reporting by Science Daily. Read the original article.
